PharmaKodex Ltd.
This article was originally published in Start Up
Executive Summary
PharmaKodex, a joint venture of Vectura Group and Unilever Ventures, is developing oral and dermal delivery systems that improve availability, thus improving drug response time and activity, leading to greater patient acceptance. The company is adding a twist to the standard low-risk reformulation model now ubiquitous in the specialty pharma world; it intends to use its technologies to develop OTC drugs that will hit market faster and bring in revenue to fund prescription drug development.
You may also be interested in...
Start-Up Previews (4/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: The Good News for Drug Delivery, features profiles of Aequus Biopharma, Macroflux, PharmaKodex, and Supernus. Plus these Start-Ups Across Health Care: Arterial Remodeling Technologies, LifeSync, Marinus Pharmaceuticals, and Tibion.
Macromolecules & Spec Pharma: The Good News in Drug Delivery
Two major changes have transformed the prospects for drug-delivery companies: the rise of spec pharma and Big Pharma's embrace of large-molecule therapeutics. A new group of start-ups represents strategies to take advantage of both opportunities.
Macromolecules & Spec Pharma: The Good News in Drug Delivery
Two major changes have transformed the prospects for drug-delivery companies: the rise of spec pharma and Big Pharma's embrace of large-molecule therapeutics. A new group of start-ups represents strategies to take advantage of both opportunities.